INTRODUCTION: The study aimed to evaluate the real-world effectiveness of adalimumab as well as investigate the persistence of treatment and identify factors, which may affect it. METHODS: More than 1150 patients (4363.1 patient-years) with psoriasis who had been treated with adalimumab since the start of the BIOREP registry in the Czech Republic were included in this analysis. Treatment effectiveness was defined as improvement in Psoriasis Area and Severity Index (PASI). The analysis was performed during the years 2005 and 2018. Patients were on on-label dose. RESULTS: After 12 and 96 months of therapy, 84% and 88% of patients had a 75% reduction in PASI score from baseline, respectively. Drug survival was analyzed according to the number of previous biological therapies, and results showed 75% and 58.1% survival rate for biologically naïve patients in the 20th and 80th month of treatment, respectively. The negative predictors of adalimumab survival were the female gender, obesity, baseline PASI score and the number of previous biological therapies. CONCLUSIONS: Baseline factors including PASI, number of previous biological therapies, and sex were associated with shorter adalimumab survival. This long-term study shows that adalimumab is effective and has high treatment persistence.

Department of Dermatovenereology 1st Faculty of Medicine and General University Hospital Charles University Prague Czech Republic

Department of Dermatovenereology 3rd Faculty of Medicine Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

Department of Dermatovenereology Faculty of Medicine and University Hospital Charles University Pilsen Czech Republic

Value Outcomes Prague Czech Republic

Zobrazit více v PubMed

Boehncke W-H, Schön MP. Psoriasis. The Lancet. 2015;386(9997):983–994. doi: 10.1016/S0140-6736(14)61909-7. PubMed DOI

Menter A. Psoriasis and psoriatic arthritis treatment. Am J Manag Care. 2016;22(8 Suppl):s225–237. PubMed

Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G, Franchi A, et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatol Basel Switz. 2018;234(1–2):1–12. PubMed

Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450–458. doi: 10.1111/bjd.17738. PubMed DOI

Amin M, Lee EB, Bhutani T, Wu JJ. Review of European registries for psoriasis. J Dermatol Treat. 2019;30(3):227–236. doi: 10.1080/09546634.2018.1506084. PubMed DOI

Kojanova M, Fialova J, Cetkovska P, Gkalpakiotis S, Jircikova J, Dolezal T, et al. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. Int J Dermatol. 2017;56(4):428–434. doi: 10.1111/ijd.13543. PubMed DOI

Humira 40 mg solution for injection in pre-filled pen—summary of Product Characteristics (SmPC) - (emc) [Internet]. [cited 2020 Mar 30]. Available from: https://www.medicines.org.uk/emc/product/7986

Overview | Adalimumab for the treatment of adults with psoriasis | Guidance | NICE [Internet]. NICE; [cited 2020 Mar 30]. Available from: https://www.nice.org.uk/guidance/ta146?unlid=8346068882016119175149

Strober B, Crowley J, Langley RG, Gordon K, Menter A, Leonardi C, et al. Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. J Eur Acad Dermatol Venereol. 2018;32(12):2126–2133. doi: 10.1111/jdv.15203. PubMed DOI

Klijn SL, van den Reek JMPA, van de Wetering G, van der Kolk A, de Jong EMGJ, Kievit W. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. Br J Dermatol. 2018;178(5):1181–1189. doi: 10.1111/bjd.16247. PubMed DOI

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Drug survival of adalimumab, ustekinumab, and secukinumab in patients with psoriasis: a prospective cohort study from the british association of dermatologists biologics and immunomodulators register (BADBIR). Br J Dermatol. 2020. PubMed

Leman J, Walton S, Layton AM, Ward KA, McBride S, Cliff S, et al. The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. J Dermatol Treat. 2020;31(3):213–221. doi: 10.1080/09546634.2019.1592096. PubMed DOI

Pogácsás L, Borsi A, Takács P, Remenyik É, Kemény L, Kárpáti S, et al. Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary. J Dermatol Treat. 2017;28(7):635–641. doi: 10.1080/09546634.2017.1329504. PubMed DOI

Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069–1076. doi: 10.1111/bjd.16776. PubMed DOI PMC

Inzinger M, Wippel-Slupetzky K, Weger W, Richter L, Mlynek A, Fleischander B, et al. Survival and effectiveness of tumour necrosis factor-alpha inhibitors in the treatment of plaque psoriasis under daily life conditions: report from the psoriasis registry Austria. Acta Derm Venereol. 2016;96(2):207–212. doi: 10.2340/00015555-2214. PubMed DOI

Belinchón I, Ramos JM, Carretero G, Ferrándiz C, Rivera R, Daudén E, et al. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. J Eur Acad Dermatol Venereol JEADV. 2017;31(10):1700–1708. doi: 10.1111/jdv.14314. PubMed DOI

Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry

Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study